文献速递食管胃疾病与幽门螺杆菌

幽门螺杆菌抗生素耐药性的流行情况:世界卫生组织区域的系统综述与荟萃分析

Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions.
PubMed 文献 · Gastroenterology · 2018-07-07

该系统综述与荟萃分析纳入178项研究、来自65个国家的66,142株分离株,评估幽门螺杆菌对克拉霉素、甲硝唑、左氧氟沙星、阿莫西林或四环素的耐药率及耐药与治疗失败的关系。结果显示除美洲和东南亚原发克拉霉素耐药率及欧洲原发左氧氟沙星耐药率外,各WHO区域原发和继发耐药率均≥15%,克拉霉素耐药与含克拉霉素方案失败显著相关(OR 6.97)。作者认为耐药已达令人担忧水平,需本地监测网络选择合适根除方案。

要点

  • 各WHO区域对克拉霉素、甲硝唑和左氧氟沙星的原发和继发耐药率多≥15%,仅美洲和东南亚原发克拉霉素耐药率及欧洲原发左氧氟沙星耐药率例外。
  • 克拉霉素耐药与含克拉霉素方案治疗失败显著相关(OR 6.97;95%CI 5.23-9.28;P<.001)。
  • 大多数WHO区域观察到抗生素耐药性增加,所有分析存在显著异质性(I²>75%)。

核心结论

  • 幽门螺杆菌抗生素耐药在全球已达令人担忧水平,对治疗疗效有很大影响,需要本地监测网络为各区域选择合适根除方案。

研究设计与样本

  • 系统综述与荟萃分析,检索评估幽门螺杆菌对克拉霉素、甲硝唑、左氧氟沙星、阿莫西林或四环素耐药率的研究,纳入178项研究、来自65个国家的66,142株分离株,按WHO区域汇总原发和继发耐药率的合并估计值及95%CI,并合并耐药与敏感分离株治疗失败的OR及95%CI。

主要发现

  • 除美洲原发克拉霉素耐药率10%(95%CI 4%-16%)、东南亚区域原发克拉霉素耐药率10%(95%CI 5%-16%)和欧洲区域原发左氧氟沙星耐药率11%(95%CI 9%-13%)外,各WHO区域对克拉霉素、甲硝唑和左氧氟沙星的原发和继发耐药率均≥15%。
  • 所有分析存在显著异质性(I²>75%),可能源于按国家分组耐药率。
  • 大多数WHO区域观察到抗生素耐药性增加。
  • 克拉霉素耐药与含克拉霉素方案治疗失败显著相关(OR 6.97;95%CI 5.23-9.28;P<.001)。

关键数值与推荐

  • 原发克拉霉素耐药率:美洲10%(95%CI 4%-16%),东南亚区域10%(95%CI 5%-16%)。
  • 原发左氧氟沙星耐药率:欧洲区域11%(95%CI 9%-13%)。
  • 克拉霉素耐药与含克拉霉素方案治疗失败的OR为6.97(95%CI 5.23-9.28;P<.001)。

临床怎么用

  • 作者认为需要本地监测网络为各区域选择合适根除方案。

局限性

  • 所有分析存在显著异质性(I²>75%),可能源于按国家分组耐药率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: In 2017, the World Health Organization (WHO) designated clarithromycin-resistant Helicobacter pylori a high priority for antibiotic research and development. However, there are no clear data on the global distribution of resistance or its clinical effects. We performed a systematic review and meta-analysis to assess the distribution of H pylori resistance to commonly used antibiotics and to measure the association between antibiotic resistance and treatment failure. METHODS: We searched publication databases for studies that assessed rates of H pylori resistance to clarithromycin, metronidazole, levofloxacin, amoxicillin, or tetracycline. Pooled estimates of primary and secondary resistance and 95% confidence intervals (CIs) were grouped by WHO region. The association between antibiotic resistance and treatment failure was measured by extracting data on treatment efficacy in patients with resistant and susceptible isolates and pooling odds ratios with 95% CIs. RESULTS: We identified 178 studies, comprising 66,142 isolates from 65 countries. Primary and secondary resistance rates to clarithromycin, metronidazole, and levofloxacin were ≥15% in all WHO regions, except primary clarithromycin resistance in the Americas (10%; 95% CI, 4%-16%) and South-East Asia region (10%; 95% CI, 5%-16%) and primary levofloxacin resistance in the European region (11%; 95% CI, 9%-13%). There was considerable heterogeneity (I2 > 75%) among all analyses-this might have resulted from the grouping of resistance rates by country. Increasing antibiotic resistance was observed in most WHO regions. Resistance to clarithromycin was significantly associated with failure of clarithromycin-containing regimens (odds ratio, 6.97; 95% CI, 5.23-9.28; P < .001). CONCLUSIONS: Resistance of H pylori to antibiotics has reached alarming levels worldwide, which has a great effect on efficacy of treatment. Local surveillance networks are required to select appropriate eradication regimens for each region.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Savoldi A, Carrara E, Graham DY, et al. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology. 2018. PMID: 29990487. doi:10.1053/j.gastro.2018.07.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。